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Introduction
A peptide inhibiting the release of growth hormone
(GH) was originally detected accidentally during studies
of the distribution of GH-releasing factor in the hypo-
thalamus of rats (1). This peptide, called somatostatin,
proved to be a cyclic peptide consisting of 14 amino
acids. Subsequent studies have considerably expanded
this initially simple concept of somatostatin as a peptide
whose main function is the regulation of GH secretion.
Somatostatin is present and plays an inhibitory role in
the regulation of several organ systems in man and
other species, such as the central nervous system, the
hypothalamus and the pituitary gland, the gastro-
intestinal tract, the endocrine and exocrine pancreas,
several components of the immune system, the
retina, and vessel walls (2, 3) Apart from the inhibition
of GH and thyrotropin (TSH) secretion, somatostatin
also inhibits a variety of other physiological functions
such as gastrointestinal motility, gastric acid pro-
duction, pancreatic enzyme secretion, bile and colonic
fluid secretion. It inhibits the secretion of hormones
such as insulin, glucagon, secretin, and vasoactive
intestinal polypeptide (2, 3). In these different activities
somatostatin acts as a neurohormone, a neurotrans-
mitter, or as a local factor acting via autocrine or para-
crine mechanisms. In his Nobel lecture, Guillemin
summarized a number of these newly discovered mech-
anisms (4). In view of the ability of somatostatin to
inhibit such a variety of physiological processes, he pre-
dicted that this peptide might be of therapeutic value in
clinical conditions involving hyperfunction of the
organ systems mentioned above. However, the multiple
simultaneous effects of pharmacological concen-
trations of somatostatin in different organs, the need
for intravenous administration, its short half-life in
the circulation, and the post-infusion hypersecretion
of hormones considerably hampered the initial enthu-
siasm, as well as its clinical use.
The development of somatostatin analogs
In 1974, two years after the discovery of somatostatin,
the Sandoz Company in Basel, Switzerland started a
program to develop long-acting analogs. Using step-
by-step modification of the conformationally stabilized,
central, essential part of the somatostatin molecule,
Bauer et al. succeeded in synthesizing an analog
which did not have most of the disadvantages of the
native peptide (5). In monkeys this analog, code
named SMS 201-995 (octreotide; H-[D]-Phe-Cys-Phe-
[D]-Trp-Lys- Thr-Cys-Thr(0L)), inhibits the secretion of
GH, glucagon and insulin 45, 11 and 1.3 times more
actively, respectively, than native somatostatin. The
analog was highly resistant to enzymatic degradation
(half-life about 2 h after subcutaneous administration),
and the subcutaneous administration of 50mg of the
drug in acromegalic patients suppressed GH for 6-8 h,
but was not followed by rebound hypersecretion of
GH (6).
In the subsequent years, large numbers of somato-
statin receptors were discovered on most human neuro-
endocrine tumors (7). These high-affinity receptors
were particularly densely and homogeneously distrib-
uted over the GH-secreting pituitary tumors of acro-
megalic patients and in carcinoid and pancreatic islet
cell tumors. Long-term therapy with octreotide was
demonstrated to control hormonal hypersecretion suc-
cessfully in about 65% of acromegalic patients (8).
Apart from instant clinical improvement, notable
tumor shrinkage was also demonstrated in most
patients (9). Also, in patients with metastatic carcinoid
disease and islet cell tumors, octreotide therapy in most
instances ameliorated most of the clinical problems
(10). Control of symptoms, such as diarrhea and flush-
ing attacks, caused by an overproduction of serotonin
or tachykinin(s), was reported in 70 to 90% of patients
with metastatic carcinoid tumors. Diarrhea, de-
hydration, and hypokalemia in patients with tumors
secreting vasoactive intestinal polypeptide, and peptic
ulceration, hypoglycemic attacks, and necrolytic skin
lesions in patients with tumors secreting gastrin, insu-
lin and glucagon, respectively, were well-controlled in
50–80% of patients treated with octreotide. Apart
from the instant improvement in quality of life, a pro-
longed survival in octreotide-treated patients with
metastasized carcinoids and islet cell tumors was
ascribed, at least in part, to a temporary inhibition of
tumor growth (10).
Octreotide had initially to be administered sub-
cutaneously two or three times daily. A long-acting
form was eventually developed which consists of 20
to 30 mg octreotide mixed with microspheres of
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DL-lactide-co-glycolide polymer, which delivers thera-
peutic octreotide levels for at least 28 days after intra-
muscular injection. Also two other cyclin analogs of
somatostatin with only slightly different activity pro-
files, vapreotide (RC-160), and lanreotide (BIM-
23014) are currently used. A slow-release formulation
of lanreotide is available, which is active for 7–14
days, while a subcutaneous autogel-preparation of
90–120 mg lanreotide with an even longer duration
of activity has recently been introduced for clinical pur-
poses in several countries.
The high density of somatostatin receptors on some
tumors, as well as the availability of potent and stable
somatostatin analogs as radioligands, made it possible
to use somatostatin-receptor scintigraphy with 123I-
Tyr3-octreotide, and subsequently with IIIln-labeled
pentetic acid-D-Phe1-octreotide for the visualization of
somatostatin receptor-positive tumors in man (11,
12). The demonstration of an effective internalization
of the somatostatin receptor complex by human
tumors was the basis for the subsequently developed
concept of targeted therapy with somatostatin analogs
coupled to cytotoxic agents or radionuclides (13 –15).
Indications and adverse effects
Today, more than 15 years after the clinical introduc-
tion of octreotide, one cannot deny that there is a cer-
tain disappointment concerning the limited number of
proven indications for the use of somatostatin analogs
in clinical medicine. Apart from acromegaly, metastatic
carcinoid disease, and Vipomas, only acute variceal
bleeding of the esophagus and the perioperative pro-
tection around pancreatic surgery have been approved
as indications for the use of octreotide in a number of
countries. Unfulfilled promises for its use in the gly-
cemic and metabolic control of diabetes, in upper
gastro-intestinal bleeding, secretory diarrhea, pan-
creatitis, and especially in the treatment of cancers,
like those of the breast, prostate and colon have in
fact dampened the enthusiasm for research with
somatostatin analogs in this field.
Still, integration of a number of previous and recent
observations might refuel the enthusiasm for renewed
studies of the potential value of somatostatin analogs
in the major and commonly occurring diseases men-
tioned above.
Early studies demonstrated that long-term adminis-
tration of somatostatin analogs, like octreotide, in
most instances only transiently inhibit physiological
actions, either because of their desensitizing actions,
or because of a compensatory reaction of local stimu-
latory factors which, in most instances, eventually
have an overriding effect (16). After seven days of
octreotide administration (100 –300mg/day), the
initial inhibitory effects on secretion of gastric acid,
amylase, trypsin and lipase diminish or even disappear
(17, 18). This desensitizing or adaptational phenom-
enon explains why long-term treatment with octreotide
causes so little adverse effects: in most cases the initially
occurring symptoms such as cramps, diarrhea, and
fatty stools disappear within 10–14 days of continuous
octreotide administration, probably as a consequence of
local adaptation in the gastrointestinal tract and exo-
crine pancreas. Only the effects on the composition of
the bile and the contractility of the gall bladder are of
longer duration and cause gall stone formation
during long-term somatostatin analog administration
in 10–30% of individuals. Fortunately, clinically sympto-
matic gall bladder disease occurs in only about 1% of
individuals per treatment year on octreotide. So, it
seems that the statement ‘each disadvantage has an
advantage’ (Johan Cruyff) also applies to octreotide:
the rapid adaptation to octreotide is favorable with
regard to its adverse effects and safety, but it limits its
successful use in the treatment of patients with func-
tional disorders of the gastro-intestinal tract and the
pancreas: short-term therapy with octreotide transi-
ently lowers the blood pressure in the abdominal
vessels, improving the control of acute variceal bleed-
ings, while it transiently suppresses pancreatic
enzyme production, improving the outcome of elective
pancreatic surgery. However, it turned out to be much
more difficult to prove effectiveness of octreotide treat-
ment on secretory diarrhea, or in the closure of intes-
tinal fistulas. Despite the obvious initial clinical
improvement in most cases, these initial effects seem
to level off during longer octreotide therapy.
Somatostatin receptor subtypes
With regard to a potential role of somatostatin analogs
in the glycemic and metabolic control of diabetes mel-
litus and in the treatment of cancer, basic research in
the field of somatostatin seems to offer at least some
explanation for the marginal efficacy of octreotide treat-
ment. The various actions of somatostatin are mediated
through specific membrane receptors, which have been
demonstrated in all target organs of somatostatin, such
as the brain, the anterior pituitary, endocrine cells of
the gastro-intestinal tract and the pancreas, some
immune cells and the retina. At least five subtypes of
the human somatostatin receptor have been cloned
and characterized (3). These subtypes (sst) are identical
in 42 to 60% of their amino acid sequence, and belong
to a superfamily of receptors with seven membrane-
spanning domains. The genes for these somatostatin
receptor subtypes are located on different chromo-
somes, suggesting different functions in different
organs. Indeed, distinct, but overlapping patterns in
the expression of these different somatostatin receptor
subtypes have been demonstrated. All five subtypes
are functionally linked to adenylate cyclase through a
coupling mechanism involving guanine nucleotide-
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binding (G) proteins. But apart from inhibition of
adenylyl cyclase activity, the different subtypes are
linked to multiple other cellular effect or systems,
including effects on phosphotyrosine phosphatases,
STAT 5 and MAP kinases, inhibition of Ca2+-influx,
activation of phospholipase A and C, as well as others
(3).
Although very preliminary, some specific physiologi-
cal regulatory roles might be attributed to these
somatostatin receptor subtypes: sst2 and sst5 are
involved in the control of GH release; sst5 seems of
importance in the control of insulin, and possibly
glucagon secretion; sst3 and to a lesser extent sst2
can induce apoptosis; sst1 and sst5 have an inhibitory
effect on the cell cycle; sst1 might be involved in angio-
genesis; the function of sst4 is largely unknown.
All five somatostatin receptor subtypes bind natural
somatostatin-14 with a similar high affinity, but there
are major differences in the binding affinities of the
different structural analogs of somatostatin. Octreotide,
lanreotide, and vapreotide bind with a high affinity to
sst2, and to a lesser extent to sst5, have a low affinity
for sst3, and do not bind to sst1 and sst4. In retrospect,
this is not surprising: octreotide was selected from a
number of other analogs because of its preferential
GH-inhibitory effect, while it hardly affected insulin
release, which is considered to be mainly regulated by
sst5 (10).
New developments in somatostatin
receptor physiology
In recent years major new developments have been
reported which have helped in the understanding of
somatostatin receptor physiology. The availability of
sst5-specific, high affinity sst2 and mixed sst2- and
sst5-specific analogs has allowed Melmed’s group to
delineate the role of sst2 and sst5 in the regulation of
pituitary hormone secretion (19, 20). Using primary
human fetal pituitary cell cultures it was demonstrated
that GH secretion was suppressed equally by analogs
preferential for either sst2 (IC50 for receptor binding
affinity, 0.19–0.42 nmol/l) or sst5 (IC50, 0.37 nmol/l).
Similar analogs with high affinity for sst2 or sst5
decreased TSH secretion by 30–40% P , 0:05:
These results demonstrated, for the first time, that not
only sst2, but also sst5 is critical for the physiological
regulation of GH and TSH (19). Subsequently, using
primary cell cultures prepared from human GH secret-
ing pituitary tumors, these investigators demonstrated
that heterologous analog combinations containing
both sst2- and sst5-selective compounds were more
potent in decreasing GH release than these analogs
used alone, or than combinations of compounds
specific for the same receptor subtype. In pure prolactin
(PRL) secreting human pituitary tumor cells hormone
release was suppressed by sst5-selective, but not by
sst2-selective analogs (20).
New fundamental insights into somatostatin receptor
physiology were presented in 2000 by Patel’s group
(21, 22). Using CHO-K1 transfected cells, these investi-
gators demonstrated ligand-induced somatostatin
receptor dimerization. Both natural somatostatin and
somatostatin analogs could produce homo- or hetero-
dimerization of the somatostatin receptor subtypes 1
and 5. Such a ligand-induced dimerization process
resulted in increased binding affinity and modified
somatostatin receptor subtypes (22). This means that
protein interaction between different members of the
somatostatin receptor subfamily are involved in a
molecular cross-talk. However, a cross-talk between
different related G protein-coupled receptor families
resulting in enhanced functional activity was also sub-
sequently demonstrated. Again, using CHO-K1 cells it
was demonstrated that dopamine receptor D2R and
sst5 interact physically through hetero-oligomerization
to create a novel receptor, which also has an enhanced
functional activity (21).
After these breathtaking new insights into somato-
statin receptor physiology, the practical consequences
of these observations rapidly became clear. Melmed’s
group which demonstrated earlier that somatostatin-
induced inhibition of GH secretion from normal
human pituitary cells is mediated through both sst2
and sst5, subsequently demonstrated that combined
addition of sst2- and sst5-selective agonists resulted in
a synergic suppression of GH releasing hormone
(GHRH)-stimulated GH release from primary fetal pitu-
itary cells, achieving 73% inhibition, which is much
higher than attained with the agonists alone (32%
and 34% respectively; P , 0:05) (23). These obser-
vations suggest that simultaneous activation of sst2
and sst5 induced a functional association of these
receptor subtypes, resulting in a synergistic suppression
of GH secretion. In subsequent studies by Jaquet’s
group in human GH-secreting pituitary tumors the
functional consequences for optimizing the medical
treatment of acromegaly became apparent (24). These
investigators quantified sst2 and sst5 mRNA expression
and the in vivo sensitivity of GH release to octreotide in
10 pituitary tumors from acromegalic patients. The
octreotide-sensitive GH secretory adenomas presented
with a high level of both sst2 and sst5 mRNA
expression. However, among 5 tumors which were
only partially sensitive to octreotide, sst2 mRNA
expression was ninefold lower, and sst5 mRNA
expression approximately sevenfold higher than in the
octreotide-sensitive tumors. In this last group of par-
tially octreotide-sensitive tumors both the sst5-preferen-
tial compound BIM-23268, but especially the sst2 and
sst5 bi-specific compound, BIM-23244, were quite
effective in suppressing GH secretion. Similarly BIM-
23244 was able to suppress PRL release from five
mixed GH/PRL-secreting adenomas by more than
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50%. These data indicate that due to the heterogeneous
expression of sst2 and sst5 receptor subtypes in GH
secreting adenomas, a bispecific analog, such as BIM-
23244 that can activate both receptors, achieves
better control of GH hypersecretion in a larger
number of acromegalic tumors than octreotide (24).
The new fundamental insights in somatostatin recep-
tor physiology opening the concept of a multi-familial
cross-talk which induces new possibilities to regulate
cellular hormonal sensitivity was recently further
demonstrated by the synthesis of a somatostatin –dopa-
mine hybrid molecule, BIM-23A387 by BioMeasure,
which has a high affinity in the nmol/l range for both
sst2 and the dopamine (DA2) receptor. Indeed, such a
hybrid molecule was demonstrated in vitro to have an
enhanced effect on PRL release. This is only the start
of the search for new therapeutic opportunities, as
the combination in one molecule of somatostatin ana-
logs with opiates and/or cytokines is now also theoreti-
cally possible (J P Moreau, personal communication).
The simultaneous expression of multiple somato-
statin receptor subtypes on the same cells in target
organs, as well as many somatostatin receptor-positive
tumors indicates that a differential coupling via the 5
sst subtypes which activate simultaneously a variety
of intracellular signaling systems are an essential part
of somatostatin function. The interactive, multireceptor
responses which now also include homo- and hetero-
dimerization and cross-talk at the membrane level
with other G protein-coupled systems is a tantalizing
new concept for drug designers.
A universal ligand: SOM-230
In this evolving picture, the Novartis company has now
introduced SOM-230, a universal compound (25). By
using a stunning technology (alanine scanning) certain
functional groups which confer affinity for the five
somatostatin receptor subtypes were transposed into a
cyclohexapeptide template. Using membranes from
sst-transfected cells for receptor binding studies, the in
vitro model of GH release by rat pituitary cells, as well
as in vivo studies of GH, glucagon and insulin release
in rats, dogs and monkeys, Bruns and his group of
investigators succeeded in synthesizing SOM-230, a
compound which binds with a high affinity to sst1,
sst2, sst3 and sst5, and with a lower affinity to sst4
(25). In this sense, one can indeed speak of a virtual
‘universal’ ligand. In rats, dogs, and rhesus monkeys,
SOM-230 potently and dose-dependently decreases
insulin-like growth factor-I (IGF-I) levels for prolonged
periods of time up to 120 days. No desensitization of
the suppressing effect of SOM-230 on IGF-I levels was
observed, which is in contrast to what has been seen
with octreotide in man. An explanation for this discre-
pant effect between SOM-230 and octreotide seems to
be the different intracellular dynamics of sst2 and
sst5. sst2 is rapidly internalized after ligand binding,
but sst5 demonstrates early recycling after internaliz-
ation, with massive re-recruitment from intracellular
stores (back) to the membrane (26). Additional charac-
teristics of SOM-230 include a very favorable T 1/2 of
nearly 24 h, as well as the preliminary evidence that
glucose levels in rats and dogs remain normal during
long-term administration, despite the powerful sst5-
mediated suppression of insulin release.
What will happen now in the field of somatostatin?
A logical direct approach for both the producers of
BIM-23244 (sst2- and sst5-specific) and SOM-230
(universal ligand) is to start phase I trials to investigate
the pharmacokinetics, toxicity and dose-range of these
new compounds. The next step will probably be a
phase II trial in acromegalic patients (both octreotide-
sensitive and octreotide-insensitive) as a proof of
principle that these compounds are effective and well
tolerated during long-term therapy. Although two-
thirds of acromegalic patients can be biochemically
‘cured’ with the currently available somatostatin ana-
logs octreotide and lanreotide, the recent data of a
high expression of sst5 mRNA, which seems to give
rise to high sst5 receptor expression, especially in
octreotide-resistant acromegalic patients, suggests
that the addition of SOM-230 and/or BIM-223244 to
the therapeutic arsenal for the medical treatment of
acromegaly will probably complement their efficacy to
close to 100% of acromegalics, including those
tumors that are mixed mammo-somatotropic. Also
dopamine-resistant or -intolerant patients with prolactin-
omas will probably benefit from treatment with these
compounds. It will be interesting to see what the event-
ual position of the GH-receptor antagonist Pegvisomant
will be in this field. This compound has the disadvan-
tage that it does not exert a direct inhibitory action
on the pituitary tumor.
SOM-230 can also, at last, give an answer to the
long-standing question, whether the sst1- and sst3-
mediated anti-tumor effects (cell cycle inhibition,
induction of apoptosis) have a clinically beneficial
effect not only in patients with inoperable carcinoids
and islet cell tumors, but also in patients with other-
wise non treatable somatostatin receptor-positive
breast, prostate and colonic cancers, as well as malig-
nant lymphomas. Careful analysis of the somatostatin
receptor subtype distribution on the tumors of the
patients included in such clinical trials is mandatory,
however. But apart from these potentially important
direct antiproliferative actions of SOM-230, the
manipulation of IGF-I bioactivity might also have
new, important clinical significance in the control of
tumor growth in a variety of solid cancers.
Finally, the use of somatostatin analogs in diabetes
mellitus remains an open, but exciting field. The long-
term control of GH and IGF-I secretion might be of
benefit in improving overnight metabolic control in
type I diabetics by suppressing GH release, and in the
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prevention of the at least partially IGF-I-dependent dia-
betic complications in the eye and kidney as well (27 –
30). In previous studies slightly initial beneficial, but
often transient effects were observed during octreotide
administration which, at least in part, were attributed
to the transient and marginal suppression in circulat-
ing IGF-I concentrations (29). Careful, placebo-
controlled randomized clinical trials will give answers
concerning the potential value of SOM-230 in the
treatment of functional gastro-intestinal disorders
such as fistulas, and in secretory diarrhea as well.
Next year it will be 30 years after the characteriz-
ation of somatostatin. A dazzling story involving contri-
butions from basic and clinical science, as well as heavy
involvement of industry bring the story of this peptide
in a full circle back to the prediction of Guillemin in
his Nobel lecture (4).
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